Lung Cancer Clinical Trials in Tennessee

Showing 401-420 of 688 trials

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

NCT05061940

The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.

Head and Neck CancerMelanomaHPV-Related Malignancy+5 more

Repertoire Immune Medicines22 participantsStarted May 2021

Scottsdale, Arizona, United States • Ann Arbor, Michigan, United States • Nashville, Tennessee, United States

TERMINATEDPhase 329 miles

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

NCT00858364

This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC). The primary objective of the study is to demonstrate that overall survival (OS) is not worse in participants on darbepoetin alfa treated to a hemoglobin ceiling of 12.0 g/dL compared to participants treated with placebo.

Non-Small Cell Lung CancerAnemiaCancer+1 more

Amgen2,549 participantsStarted Jul 2009

Anniston, Alabama, United States • Birmingham, Alabama, United States • Anchorage, Alaska, United States +563 more locations

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Lung Cancer Trials in Other Cities

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

A Study of LY3023414 in Participants With Advanced Cancer

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Evaluation of GLR2007 for Advanced Solid Tumors

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

A Study of PLX2853 in Advanced Malignancies.

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Other Conditions in Tennessee